Property | Value |
?:abstract
|
-
People with chronic diseases represent a population at major risk of infection and complications from Sars-Cov-2 (COVID-19). Diabetes represents one of the most important comorbidities related to the severity of viral infection caused by the new Sars-Cov-2. Diabetes patients have a higher risk of serious complications caused by Sars-Cov-2 infection, such as severe acute respiratory syndrome, a hyperinflammatory state associated with multi-organ dysfunction. Given the importance of the link between COVID-19 and diabetes, it is essential to better manage glycemic normalization and infection in this category of patients to avoid serious complications. However, for some antidiabetes agents, there is evidence of efficacy against Sars-Cov-2 extra glycemic normalization. The objective of this article is to provide an overview of the potential therapeutic benefits to fight Sars-Cov-2 infection with antidiabetic agents.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
|
?:doi
|
-
10.1007/s42399-020-00608-2
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/1d033ea00aca78abc7bc0690aacd2b2081480e99.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7585556.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Antidiabetes Agents against Sars-Cov-2 Infection
|
?:type
|
|
?:year
|
|